Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Smoldering Multiple Myeloma Clinical Trial

Official title:

A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04850846
• Other study ID #: 21-008
• Secondary ID: K22CA251648
• Status: Recruiting
• Phase: Phase 2
• Start date: April 27, 2021
• Est. completion date: July 31, 2025

Study information

• Verified date: June 2024
• Source: Dana-Farber Cancer Institute
• Contact: Catherine R Marinac, PhD
• Phone: 617-632-4703
• Email: CatherineR_Marinac[@]dfci.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma.

The names of the study drug involved in this study is:

• Metformin, extended release

• Placebo ( a pill that has no active ingredients)

Description:

This is a Phase 2, double-blind, randomized placebo-controlled trial in patients with higher-risk monoclonal gammopathy of undetermined significance (MGUS) and low-risk smoldering multiple myeloma (SMM) to test the efficacy of metformin in reducing clinical indicators of disease progression in MGUS and SMM patients.

Metformin is considered "investigational", which means it has not been approved for the study of cancer prevention by the United States Food and Drug Administration. It has been approved for other uses including for blood sugar control in some people with Type II diabetes.

Multiple myeloma is a cancer of the plasma cells, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment. There are currently no approved therapies for MGUS and SMM patients.

Metformin is a medication that is commonly used in the treatment of diabetes. Metformin works by decreasing glucose production in the liver, decreasing glucose absorption, and improving insulin sensitivity. This study is interested in studying this medication because several recent studies indicate that the drug may help prevent progression in patients with MGUS or SMM. This study is looking to learn more about whether metformin will benefit patients with MGUS or SMM who may not have diabetes.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

After enrollment participants will be randomized assigned to receive either the Placebo or Metformin pills and to take them for 6 months depending on participant tolerance to the drug.

Participants will have the option to learn their treatment assignment after primary (6-month) outcome assessments are complete, and individuals randomized to metformin will have the opportunity to continue to take metformin for an additional 6-months to allow for the observation of potentially longer-term treatment response. Participants who choose to be unblinded and are taking placebo will discontinue study medication.

It is expected that about 80 people will take part in this research study.

The National Cancer Institute of the National Institutes of Health is supporting this trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: July 31, 2025
• Est. primary completion date: January 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

-Diagnosed with higher-risk MGUS or low-risk SMM defined below:

--Higher-Risk MGUS: bone marrow plasma cell concentration <10%# AND either serum M-protein level =1.5 g/dL to <3 g/dL or abnormal free light-chain (FLC) ratio (<0.26 or>1.65) or IgA MGUS.

Note: individuals with an abnormal FLC ratio that are classified as light-chain only are eligible. Light-chain only patients are defined as complete loss of immunoglobulin heavy-chain, accompanied by abnormal FLC ratio with an increased level of the appropriate involved light-chain (increased kappa FLC in patient with ratio >1.65, and increased lambda FLC in patients with ratio <0.26).

• Low-Risk Smoldering Myeloma: bone marrow plasma cells =10%# with the absence of additional high-risk features, which are further defined in the exclusion criteria

#A new bone marrow biopsy is preferred for plasma cell determination at screening; however, determination of eligibility can be made from most recent bone marrow biopsy performed as long as it was within 2 years of enrollment.

• Absence of evidence of CRAB criteria* or new criteria of active MM or active WM which including the following (note if one or more criteria has not been evaluated (e.g., no MRI), the criteria for active MM or WM for that feature is considered unmet):

• Increased calcium levels (corrected serum calcium >0.25 mmol/dL above the upper limit of normal or >.275 mmol/dL) related to MM

• Renal insufficiency (attributable to MM)

• Anemia (Hb 2g/dL below the lower limit of normal or <10g/dL) related to MM

• Bone lesions (lytic lesions or generalized osteoporosis with compression fractures)

• Bone marrow plasma cells =60%

• Serum involved/uninvolved FLC ratio =100, provided the absolute level of the involved free light chain is at least 100 mg/L and repeated twice (light chain smoldering myeloma as described in section 2.4 is not an exclusion criteria).

• MRI with two or more focal lesion that is at least 5 mm or greater in size

*Participants with CRAB criteria that are attributable to conditions other than the disease under study may be eligible

• At least 18 years of age.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• The following laboratory values obtained prior to the first dose of study drug/placebo:

• AST and ALT < 1.5 x institutional ULN

• Serum bilirubin < institutional ULN (in patients with Gilbert's Disease, direct bilirubin < institutional ULN)

• Calculated creatinine clearance = 45 mL/min

• Estimation of renal function will be assessed using the CrCl calculated based on the Cockcroft-Gault formula:

• CrCl (mL/min) = (140-age) (weight [kg]/72 (serum creatinine [mg/dL]; for females the formula is multiplied by 0.85

• Random glucose < 160 mg/dL or fasting glucose < 126 mg/dL (other values require workup to rule out undiagnosed diabetes that may require treatment)

• Ability to understand and the willingness to sign a written informed consent document

• For participants who wish to enroll in the open label extended treatment (crossover arm), participants can be unblinded and learn of their drug group AFTER completing primary endpoint collection. Patient must be randomized to metformin in order to continue taking metformin for 6 additional months.

Exclusion Criteria:

• Presence of high-risk smoldering myeloma, as defined by per IMWG/Mayo 2018 "20-2-20" Criteria (at least 2 of the following)

• Bone marrow plasmacytosis =20%

• =2g/dl M protein

• =20 involved: uninvolved serum free light chain ratio

• Diagnosed or treated for another malignancy within the study period.

• Currently on medications for diabetes treatment

• Patients with hyperglycemia (random glucose < 160 mg/dL or fasting glucose < 126 mg/dl) but who are not on any drug treatment are eligible

• Participants who are receiving any other investigational agents.

• Women who are pregnant or who are unable or unwilling to use contraception during the study period are excluded from this study because it is a class B agent which is known to cross the placenta rapidly and is unbound in serum.

• Any condition associated with increased risk of metformin-associated lactic acidosis (prior renal failure or liver failure, history of acidosis of any type) or habitual intake of 3 or more alcoholic beverages per day.

• Known intolerance to metformin

• Known malabsorption syndrome or diagnosis with a medical condition that may alter gastrointestinal absorption of medications including but not limited to inflammatory bowel disease impacting the small intestine or recent history of bariatric surgery.

• Any other condition that, in the investigator's judgment, would contraindicate the use of metformin or otherwise interfere with participation in the trial

Related Conditions & MeSH terms

• Monoclonal Gammopathy of Undetermined Significance
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Paraproteinemias
• Smoldering Multiple Myeloma

Intervention

Drug:
• Metformin XR
Orally by mouth

Other:
• Placebo
Orally by mouth

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Dana-Farber at Brighton	Brighton	Massachusetts
United States	Dana-Farber at NHOH	Londonderry	New Hampshire
United States	Dana-Farber at Merrimack Valley	Methuen	Massachusetts
United States	Dana-Farber at Milford	Milford	Massachusetts
United States	DF/ BWCC in Clinical Affiliation with South Shore Hospital	Weymouth	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	(M-)protein concentrations/light chains change	Assessed by using the serum-protein electrophoresis and serum-free light chain assays	Baseline to 6-months
Secondary	(M-)protein concentrations/light chains change by mass spectrometry		Baseline to 6-months
Secondary	Hemoglobin concentrations change		Baseline to 6-months
Secondary	Hemoglobin A1c (HbA1c) concentrations change		Baseline to 6-months
Secondary	Molecular evolution of CD138+ cells		Baseline to 6-months
Secondary	Molecular evolution of immune cells (CD138- or CD45+)		Baseline to 6-months
Secondary	Changes in plasma metabolites measured by liquid chromatography-mass spectrometry		Baseline to 6-months
Secondary	Changes in PROMIS Global Health Summary Score v1.2		Baseline to 6-months
Secondary	Number of participants willing to continue to take metformin beyond 6 month primary assessment period		Baseline- 12 months
Secondary	Changes in response for those who choose to take metformin for up to 1 year per IMWG response criteria		Baseline- 12 months